What is Dimension Inx?
Dimension Inx operates as a specialized leader in the biofabrication industry, focusing on the intersection of tissue engineering and advanced manufacturing. The company's core technology, a 3D-Painting platform, provides the necessary versatility and cost-efficiency to transition regenerative medicine from experimental research into widespread clinical adoption. By partnering with leading medical product manufacturers and surgical experts, Dimension Inx is positioning itself as a foundational infrastructure provider for the next generation of medical devices. The company's strategic focus on manufacturability ensures that its regenerative products are not only scientifically robust but also commercially viable for global healthcare systems. This dual focus on innovation and scalability is central to its mission of transforming patient outcomes through high-precision biological material design.
How much funding has Dimension Inx raised?
Dimension Inx has raised a total of $15.2M across 3 funding rounds:
Unspecified
$35K
Angel/Seed
$3.2M
Series A
$12M
Unspecified (2019): $35K, investors not publicly disclosed
Angel/Seed (2020): $3.2M led by Rise of the Rest Seed Fund, KdT Ventures,, and Better Ventures
Series A (2023): $12M supported by KdT Ventures and Prime Movers Lab
Key Investors in Dimension Inx
Better Ventures
Better Ventures is a mission-driven venture capital firm that invests in early-stage startups focusing on leveraging science and technology to create a sustainable economy that benefits people and the planet.
KdT Ventures
KdT Ventures is a venture capital firm specializing in early-stage frontier science investing, focusing on transformative technologies in medicine, chemicals, and materials.
Prime Movers Lab
Prime Movers Lab is a venture capital firm that focuses on funding breakthrough scientific startups aimed at transforming industries and improving lives.
What's next for Dimension Inx?
With the recent influx of capital, Dimension Inx is poised to accelerate its commercialization roadmap and expand its collaborative network with top-tier medical institutions. The company is expected to prioritize the optimization of its manufacturing systems to meet the rigorous regulatory standards required for widespread clinical deployment. As it moves beyond the initial development phases, the focus will likely shift toward scaling production capacity and deepening its intellectual property portfolio in materials science. Investors are closely monitoring the firm's ability to translate its technical breakthroughs into tangible, market-ready regenerative therapies. The strategic deployment of these funds will be critical in maintaining the company's competitive edge in the rapidly evolving biofabrication landscape, ensuring that its 3D-Painting technology becomes a standard tool in the surgeon's arsenal for treating complex debilitations.
See full Dimension Inx company page
